Hypertensive epigenetics: From DNA methylation to microRNAs

Journal of Human Hypertension

Volumn 29, Issue 10, 2015, Pages 575-582

  Wang, J ^a   Gong, L ^a   Tan, Y ^a   Hui, R ^a   Wang, Y ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ANGIOTENSINOGEN; BETA 1 ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; EPITHELIAL SODIUM CHANNEL; HISTONE; MICRORNA; MICRORNA 126; MICRORNA 132; MICRORNA 145; MICRORNA 181A; MICRORNA 212; MICRORNA 296; MICRORNA 31; MICRORNA 483 3P; MICRORNA 584; MICRORNA 663; MICRORNA 9; PROTEIN KINASE WNK4; RENIN; SODIUM POTASSIUM CHLORIDE COTRANSPORTER 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

AREA POSTREMA; DNA METHYLATION; EPIGENETICS; ESSENTIAL HYPERTENSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; NERVE CELL; NONHUMAN; PROMOTER REGION; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETICS; HYPERTENSION;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; HYPERTENSION; MICRORNAS;

EID: 84941258789     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.132     Document Type: Review

References (89)

1. Pausova Z, Tremblay J, Hamet P. Gene-environment interactions in hypertension. Curr Hypertens Rep 1999; 1(1): 42-50.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217-223.
4. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288(15): 1882-1888.
5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al.evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 311(5): 507-520.
6. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139(9): 761-776.
7. Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep 2010; 12 (1): 17-25.
8. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res 2009; 58(Suppl 2): S33-S41.
9. Millis RM. Epigenetics and hypertension. Curr Hypertens Rep 2011; 13(1): 21-28.
10. Udali S, Guarini P, Moruzzi S, Choi SW, Friso S. Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol Aspects Med 2013; 34(4): 883-901.
11. Webster AL, Yan MS, Marsden PA. Epigenetics and cardiovascular disease. Can J Cardiol 2013; 29(1): 46-57.
12. Ordovás JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol 2010; 7(9): 510-519.
13. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007; 213(2): 384-390.
14. Rottach A, Leonhardt H, Spada F. DNA methylation-mediated epigenetic control. J Cell Biochem 2009; 108(1): 43-51.
15. Yan J, Zierath JR, Barrès R. Evidence for non-CpG methylation in mammals. Exp Cell Res 2011; 317(18): 2555-2561.
16. Mariniello B, Ronconi V, Sardu C, Pagliericcio A, Galletti F, Strazzullo P et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens 2005; 18(8): 1091-1098.
17. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004; 13(4): 451-458.
18. Ferrari P. The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 2010; 1802(12): 1178-1187.
19. Campino C, Carvajal CA, Cornejo J, San Martín B, Olivieri O, Guidi G et al. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension. Endocrine 2010; 37(1): 106-114.
20. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 2004; 114(8): 1146-1157.
21. Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V et al. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 2008; 199(2): 323-327.
22. Howard TE, Shai SY, Langford KG, Martin BM, Bernstein KE. Transcription of tes-ticular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene. Mol Cell Biol 1990; 10(8): 4294-4302.
23. Andrade MC, Quinto BM, Carmona AK, Ribas OS, Boim MA, Schor N et al. Purification and characterization of angiotensin I-converting enzymes from mesangial cells in culture. J Hypertens 1998; 16(12 Pt 2): 2063-2074.
24. Duncan AM, Burrell LM, Kladis A, Campbell DJ. Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myo-cardial infarction. J Cardiovasc Pharmacol 1996; 28(6): 746-754.
25. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 2004; 43(4): 854-859.
26. Riviere G, Lienhard D, Andrieu T, Vieau D, Frey BM, Frey FJ. Epigenetic regulation of somatic angiotensin-converting enzyme by DNA methylation and histone acetylation. Epigenetics 2011; 6(4): 478-489.
27. Rangel M, dos Santos JC, Ortiz PH, Hirata M, Jasiulionis MG, Araujo RC et al. Modification of epigenetic patterns in low birth weight children: importance of hypomethylation of the ACE gene promoter. PLoS ONE 2014; 9(8): e106138.
28. Gamba G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol Rev 2005; 85(2): 423-493.
29. Chipperfield AR, Harper AA. Chloride in smooth muscle. Prog Biophys Mol Biol 2000; 74(3-5): 175-221.
30. Orlov SN, Tremblay J, Hamet P. NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function. Curr Opin Nephrol Hypertens 2010; 19(2): 163-168.
31. Anfinogenova YJ, Baskakov MB, Kovalev IV, Kilin AA, Dulin NO, Orlov SN. Cell-volume-dependent vascular smooth muscle contraction: role of Na+, K+, 2Cl-cotransport, intracellular Cl-and L-type Ca2+ channels. Pflugers Arch 2004; 449(1): 42-55.
32. Giménez I. Molecular mechanisms and regulation of furosemide-sensitive Na-K-Cl cotransporters. Curr Opin Nephrol Hypertens 2006; 15(5): 517-523.
33. Moriguchi T, Urushiyama S, Hisamoto N, Iemura S, Uchida S, Natsume T et al. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. J Biol Chem 2005; 280(52): 42685-42693.
34. Zagórska A, Pozo-Guisado E, Boudeau J, Vitari AC, Rafiqi FH, Thastrup J et al. Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol 2007; 176(1): 89-100.
35. Richardson C, Alessi DR. The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci 2008; 121(Pt 20): 3293-3304.
36. Vitari AC, Thastrup J, Rafiqi FH, Deak M, Morrice NA, Karlsson HK et al. Functional interactions of the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Biochem J 2006; 397(1): 223-231.
37. Bergaya S, Faure S, Baudrie V, Rio M, Escoubet B, Bonnin P et al. WNK1 regulates vasoconstriction and blood pressure response to α 1-adrenergic stimulation in mice. Hypertension 2011; 58(3): 439-445.
38. Lee HA, Baek I, Seok YM, Yang E, Cho HM, Lee DY et al. Promoter hypomethylation upregulates Na+-K+-2Cl-cotransporter 1 in spontaneously hypertensive rats. Biochem Biophys Res Commun 2010; 396(2): 252-257.
39. Cho HM, Lee HA, Kim HY, Han HS, Kim IK. Expression of Na+-K+-2Cl-cotran-sporter 1 is epigenetically regulated during postnatal development of hypertension. Am J Hypertens 2011; 24(12): 1286-1293.
40. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995; 25(3): 320-326.
41. Matsuoka Y, Li X, Bennett V. Adducin: structure, function and regulation. Cell Mol Life Sci 2000; 57(6): 884-895.
42. Manunta P, Barlassina C, Bianchi G. Adducin in essential hypertension. FEBS Lett 1998; 430(1-2): 41-44.
43. Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L et al. Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996; 97(12): 2815-2822.
44. Zhang LN, Liu PP, Wang L, Yuan F, Xu L, Xin Y et al. Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension. PLoS ONE 2013; 8 (5): e63455.
45. Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 2000; 101(6): 682-688.
46. Kong H, Li X, Zhang S, Guo S, Niu W. The β1-adrenoreceptor gene Arg389Gly and Ser49Gly polymorphisms and hypertension: a meta-analysis. Mol Biol Rep 2013; 40 (6): 4047-4053.
47. Wang H, Liu J, Liu K, Liu Y, Wang Z, Lou Y et al. β1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-a-nalysis. Mol Biol Rep 2013; 40(6): 4055-4063.
48. Jiang Q, Yuan H, Xing X, Liu J, Huang Z, Du X. Methylation of adrenergic β1 receptor is a potential epigenetic mechanism controlling antihypertensive response to metoprolol. Indian J Biochem Biophys 2011; 48(5): 301-307.
49. Zhang D, Yu ZY, Cruz P, Kong Q, Li S, Kone BC. Epigenetics and the control of epithelial sodium channel expression in collecting duct. Kidney Int 2009; 75(3): 260-267.
50. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19(10): 1845-1854.
51. Christensen BM, Perrier R, Wang Q, Zuber AM, Maillard M, Mordasini D et al. Sodium and potassium balance depends on αENaC expression in connecting tubule. J Am Soc Nephrol 2010; 21(11): 1942-1951.
52. Thomas CP, Itani OA. New insights into epithelial sodium channel function in the kidney: site of action, regulation by ubiquitin ligases, serum-and glucocorticoid-inducible kinase and proteolysis. Curr Opin Nephrol Hypertens 2004; 13(5): 541-548.
53. Zhang W, Xia X, Reisenauer MR, Rieg T, Lang F, Kuhl D et al. Aldosterone-induced Sgk1 relieves Dot1a-Af9-mediated transcriptional repression of epithelial Na+ channel alpha. J Clin Invest 2007; 117(3): 773-783.
54. Stokes JB, Sigmund RD. Regulation of rENaC mRNA by dietary NaCl and steroids: organ, tissue, and steroid heterogeneity. Am J Physiol 1998; 274(6 Pt 1): C1699-C1707.
55. Yu Z, Kong Q, Kone BC. Aldosterone reprograms promoter methylation to regulate αENaC transcription in the collecting duct. Am J Physiol Renal Physiol 2013; 305(7): F1006-F1013.
56. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet 2010; 11(4): 285-296.
57. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007; 128(4): 635-638.
58. Kang TJ, Yuzawa S, Suga H. Expression of histone H3 tails with combinatorial lysine modifications under the reprogrammed genetic code for the investigation on epigenetic markers. Chem Biol 2008; 15(11): 1166-1174.
59. Woldanska-Okonska M, Czernicki J. [Biological effects produced by the influence of low frequency electromagnetic fields on hormone secretion]. Przegl Lek 2003; 60(10): 657-662.
60. Irmak MK, Sizlan A. Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. Med Hypotheses 2006; 66(5): 1000-1007.
61. Sharma R, Ottenhof T, Rzeczkowska PA, Niles LP. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J Pineal Res 2008; 45(3): 277-284.
62. Morimoto S, Sasaki S, Itoh H, Nakata T, Takeda K, Nakagawa M et al. Sympathetic activation and contribution of genetic factors in hypertension with neurovascular compression of the rostral ventrolateral medulla. J Hypertens 1999; 17(11): 1577-1582.
63. Mao J, Li C, Zhang Y, Li Y, Zhao Y. Human with-no-lysine kinase-4 3′-UTR acting as the enhancer and being targeted by miR-296. Int J Biochem Cell Biol 2010; 42(9): 1536-1543.
64. Kahle KT, Wilson FH, Leng Q, Lalioti MD, O'Connell AD, Dong K et al. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet 2003; 35(4): 372-376.
65. Nguyen Dinh Cat A, Ouvrard-Pascaud A, Tronche F, Clemessy M, Gonzalez-Nunez D, Farman N et al. Conditional transgenic mice for studying the role of the gluco-corticoid receptor in the renal collecting duct. Endocrinology 2009; 150(5): 2202-2210.
66. Mu S, Shimosawa T, Ogura S, Wang H, Uetake Y, Kawakami-Mori F et al. Epigenetic modulation of the renal beta-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 2011; 17(5): 573-580.
67. Li M, Zhao Y, Li Y, Li C, Chen F, Mao J et al. Upregulation of human with-no-lysine kinase-4 gene expression by GATA-1 acetylation. Int J Biochem Cell Biol 2009; 41 (4): 872-878.
68. Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem 2006; 281(26): 18059-18068.
69. Lee JY, Prineas RJ, Eaton JW. Heritability of erythrocyte sodium permeability: a possible genetic marker for hypertension. Ann Clin Lab Sci 2009; 39(3): 241-250.
70. Reisenauer MR, Anderson M, Huang L, Zhang Z, Zhou Q, Kone BC et al. AF17 competes with AF9 for binding to Dot1a to up-regulate transcription of epithelial Na+ channel alpha. J Biol Chem 2009; 284(51): 35659-35669.
71. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adeno-sines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
72. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14(10A): 1902-1910.
73. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009; 457(7228): 405-412.
74. Liang M, Liu Y, Mladinov D, Cowley AW, Trivedi H, Fang Y et al. MicroRNA: a new frontier in kidney and blood pressure research. Am J Physiol Renal Physiol 2009; 297(3): F553-F558.
75. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-297.
76. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011; 3(3): 83-92.
77. Clifford RL, Singer CA, John AE. Epigenetics and miRNA emerge as key regulators of smooth muscle cell phenotype and function. Pulm Pharmacol Ther 2013; 26(1): 75-85.
78. Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA 2008; 105(39): 14879-14884.
79. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12(12): 861-874.
80. Mopidevi B, Ponnala M, Kumar A. Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding. Physiol Genomics 2013; 45(19): 901-906.
81. Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension 2011; 58(6): 1093-1098.
82. Kemp JR, Unal H, Desnoyer R, Yue H, Bhatnagar A, Karnik SS. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol 2014; 75: 25-39.
83. Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 2010; 285(16): 11903-11912.
84. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15(2): 272-284.
85. Bátkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 2012; 14(1): 79-87.
86. Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. J Am Soc Hypertens 2014; 8(6): 368-375.
87. Santovito D, Mandolini C, Marcantonio P, De Nardis V, Bucci M, Paganelli C et al. Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients. Expert Opin Ther Targets 2013; 17(3): 217-223.
88. Sayed AS, Xia K, Salma U, Yang T, Peng J. Diagnosis, prognosis and therapeutic role of circulating mirnas in cardiovascular diseases. Heart Lung Circ 2014; 23(6): 503-510.
89. Eskildsen TV, Jeppesen PL, Schneider M, Nossent AY, Sandberg MB, Hansen PB et al. Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci 2013; 14(6): 11190-11207.